Related to Intrinsic Bioprobes Enters $1.27M Contract with NCI for Detection of Low-Abundance, Cancer-Related Proteins

• Intrinsic Licenses Two Type 2 Diabetes Markers to Ortho-Clinical Diagnostics
  
• NanoString’s Gene-Expression Technology to Be Used by NCI
  
• NCI to Conduct Phase I Study with Immatics' Glioblastoma Vaccine
  
• Caliper’s microCT Imaging Device to Be Used in NCI’s Preclinical Lung Cancer Studies
  
• NCI Taps GNS to Find Biomarkers Using Computational Models
  
• ICR to Use AB Sciex Mass Spec System in Cancer Metastasis Research
  
• Proteome Sciences and Moffitt Cancer Center Ally on Mass Spec-Based Clinical Assays
  
• Pharmacyclics Secures Five-Year CRADA with NCI to Develop Blood Cancer Drug
  
• NCI/NHGRI Taps Horizon's Gene-Editing Platform
  
• Study Shines a Light on Colorectal Cancer
  
• Grant Won to Evaluate Glucose Uptake Inhibitor in Brain Cancer
  
• Kite, NCI Partner on Engineered Autologous T-Cell Therapies
  
• NCI Grants MabVax $150K for Neuroblastoma Vaccine
  
• NCI to Undertake IND-Enabling Studies for Azaya’s Anticancer Agent
  
• Ortho Biotech Joins Forces with NCI to Test Firm's Immunotherapy in Cancer
  
• Roche Sequence Capture and Genome Sequencing Technologies to Be Evaluated for Cancer Genetics
  
• Astex Signs CRADA with NCI to Investigate Its Small Molecule Therapeutic
  
• NCI to Evaluate Cornerstone’s Emulsiphan Tech to Deliver New Class of Cytotoxic Agents
  
• Exelixis, NCI to Develop Cabozantinib Against Multiple Cancers
  
• Exelixis Broadens Cabozantinib Program Through CRADA with NCI-CTEP